Molecular mechanisms involved with neuroendocrine diseases such as obesity and diabetes are closely linked to insulin resistance and require attention since metabolic dysfunction has also been associated with neurodegeneration. The global increase in these chronic diseases support a role for lipids such as ceramide and its metabolites in the pathogenesis of these diseases (1). The link between the ceramide and its pathogenesis of diabetes (2) has been an important discovery that may assist with the role of ceramide in the pathogenesis of Alzheimer’s disease (AD) also referred to as Type 3 diabetes (3). Lipids such as cholesterol and ceramide have been connected to processing of the amyloid precursor protein with generation or regulation of beta-amyloid production that is central to the amyloid hypothesis in AD. The cholesterol-ceramide connection has been previously linked with aging and AD. Lipidomic analysis using mass spectrometry of fasting plasma from an ageing cohort (AIBL) that include cognitively healthy controls and AD patients at baseline have been provided in this study. The plasma lipid ceramide was elevated with alteration in other lipids in AD patients and this study provides potential for early therapeutic targets that reduce ceramide levels to manage hypercholesterolemia and insulin resistance in both diabetes and AD. 1.Chavez JA. Cell Metab. 2012.2. Galadari S. Lipids Health Dis.2013. 3. De la Monte, S.M. J Diab. Sci.Tech.2008.
|Published - 3 Nov 2014
|5th World Congress on Diabetes and Metabolism - Las Vegas, United States
Duration: 3 Nov 2014 → 5 Nov 2014
|5th World Congress on Diabetes and Metabolism
|3/11/14 → 5/11/14